Abstract
The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported. She experienced severe amphotericin-B-related side-effects in spite of pretreatment, but was subsequently successfully treated with 3 g of a small unilamellar liposome formulation of amphotericin B prepared from soya phosphatidylcholine and cholesterol in a 7∶3 molar ratio at our institute. The patient experienced minimal side-effects with this preparation, although no pretreatment was given. Liposomal amphotericin B prepared in our institute appears to be a safe and effective therapy for systemic fungal infections. However, large controlled studies are required to determine more precisely the potential of liposomal amphotericin B in the treatment of severe systemic fungal infection.
This is a preview of subscription content, log in via an institution to check access.
References
Bodey GP (1984) Candidiasis in cancer patients. Am J Med 77:13–19
Gokhale PC, Kotwani RN, Dange SY, Kshirsagar NA, Pandya SK (1993) Preclinical and pharmaceutical testing of liposomal amphotericin B. Ind J Med Res 98:75–79
Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK (1993) Pharmacokinetics and tolerability of liposomal amphotericin B in patients. J Antimicrob Chemother (in press)
Haron E, Feld R, Ruffnell P, Patterson B, Hasselback R, Matlow A (1987) Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 83:17–26
Hawkins C, Armstrong D (1984) Fungal infections in the immunocompromised host. Clin Haematol 13:599–630
Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151:704–710
Maddux MS, Barriere SL (1980) A review of complications and amphotericin B therapy: recommendations for prevention and management. Drug Intel Clin Pharm 14:177–181
Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28 [Suppl B]:73–82
Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24:527–538
Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA (1986) Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 9:349–353
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gokhale, P.C., Barapatre, R.J., Advani, S.H. et al. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol 119, 569–571 (1993). https://doi.org/10.1007/BF01372718
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01372718